# US 2024/0200147 A1 · Non-Small Cell Lung Cancer Diagnosis and Treatment > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0200147 A1 - Document ID: US20240200147A1 - Status: Published application - Kind: A1 - Application number: 18/517,623 - Filed: 2023-11-22 - Published: 2024-06-20 - Earliest claimed: 2022-11-22 - Assignees: West Virginia University Board of Governors on behalf of West Virginia University - Applicants: West Virginia University Board of Governors on Behalf of West Virginia University - Inventors: Nancy Lan Guo - Web page: https://patentgrep.com/patent/US20240200147A1 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol - A61K 31/277: having a ring, e.g. verapamil - A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine - A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine - A61P 35/00: Antineoplastic agents - G01N 33/5752: of the lungs - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/118: Prognosis of disease development - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/158: Expression markers - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract This invention provides a method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306 or pharmaceutically acceptable salts thereof, U-0126 or pharmaceutically acceptable salts thereof, ZM-306416 or pharmaceutically acceptable salts thereof, and PQ-401 or pharmaceutically acceptable salts thereof, for treating non-small cell lung cancer in said patient. This invention provides a method for producing an immune response in a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306, U-0126, ZM-306416, and PQ-401, for producing an immune response in said patient. ## Claims ### Claim 1 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306 or pharmaceutically acceptable salts thereof, U-0126 or pharmaceutically acceptable salts thereof, ZM-306416 or pharmaceutically acceptable salts thereof, and PQ-401 or pharmaceutically acceptable salts thereof, for treating non-small cell lung cancer in said patient. ### Claim 2 (depends on 1) The method of claim 1 including wherein said compound is PD-198306 or pharmaceutically acceptable salts thereof. ### Claim 3 (depends on 1) The method of claim 1 including wherein said compound is U-0126 or pharmaceutically acceptable salts thereof. ### Claim 4 (depends on 1) The method of claim 1 including wherein said compound is ZM-306416 or pharmaceutically acceptable salts thereof. ### Claim 5 (depends on 1) The method of claim 1 including wherein said compound is PQ-401 or pharmaceutically acceptable salts thereof. ### Claim 6 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of PD-198306 or pharmaceutically acceptable salts thereof, U-0126 or pharmaceutically acceptable salts thereof, ZM-306416 or pharmaceutically acceptable salts thereof, and PQ-401 or pharmaceutically acceptable salts thereof, and a therapeutically acceptable pharmaceutical carrier, for treating non-small cell lung cancer in said patient. ### Claim 7 A method for producing an immune response in a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of PD-198306, U-0126, ZM-306416, and PQ-401, for producing an immune response in said patient. ### Claim 8 A method for producing an immune response in a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of PD-198306, U-0126, ZM-306416, and PQ-401, and a therapeutically acceptable pharmaceutical carrier, for producing an immune response in said patient. ### Claim 9 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound that is a MEK1/2 inhibitor selected from the group consisting of PD-198306 and U-0126. ### Claim 10 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a composition comprising a compound that is a MEK1/2 inhibitor selected from the group consisting of PD-198306 and U-0126, and a therapeutically acceptable pharmaceutical carrier. ### Claim 11 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound that is a VEGFR inhibitor that is ZM-306416. ### Claim 12 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a composition comprising a compound that is a VEGFR inhibitor that is ZM-306416, and a therapeutically acceptable pharmaceutical carrier for treating a patient having non-small cell lung cancer. ### Claim 13 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a compound that is a IGF-1R inhibitor that is PQ-401. ### Claim 14 A method of treating a patient having non-small cell lung cancer comprising administering to said patient a therapeutically effective amount of a composition comprising a compound that is a IGF-1R inhibitor that is PQ-401 and a therapeutically acceptable pharmaceutical carrier for treating a patient having non-small cell lung cancer. ### Claim 15 A method of diagnosis and screening of non-small cell lung cancer comprising using protein expression levels of one elected from the group consisting of ABCC4, DAG1, and SLC39A8 in patient samples, of ABCC4 and DAG1 in patient samples, of ABCC4 and SLC39A8 in patient samples, of DAG1 and SLC39A8 in patient samples, of ABCC4 in patient samples, of DAG1 in patient samples, and of SLC39A8 in patient samples. ### Claim 16 A method of diagnosis and screening of non-small cell lung cancer comprising using mRNA expression levels of ABCC4, CCL19, CD27, DAG1, FUT7, and ZNF71 in patient samples.